Future Challenges for Drug Development in Renal Cell Carcinoma

被引：5
作者：
Rini, Brian I. [1 ]
Vogelzang, Nicholas J. [2 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] US Oncol Res, Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
PHASE-II; SUNITINIB; THERAPY; TRIAL; CABOZANTINIB; SORAFENIB; DESIGN; MET;
D O I：
10.1200/JCO.2016.71.0673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：577 / +
页数：4
相关论文
共 19 条
[1]   Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules [J].
Atkinson, Bradley J. ;
Kalra, Sarathi ;
Wang, Xuemei ;
Bathala, Tharakeswara ;
Corn, Paul ;
Tannir, Nizar M. ;
Jonasch, Eric .
JOURNAL OF UROLOGY, 2014, 191 (03) :611-618
[2]   Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success? [J].
Chan, John K. ;
Ueda, Stefanie M. ;
Sugiyama, Valerie E. ;
Stave, Christopher D. ;
Shin, Jacob Y. ;
Monk, Bradley J. ;
Sikic, Branimir I. ;
Osann, Kathryn ;
Kapp, Daniel S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1511-1518
[3]   Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].
Choueiri, Toni K. ;
Halabi, Susan ;
Sanford, Ben L. ;
Hahn, Olwen ;
Michaelson, M. Dror ;
Walsh, Meghara K. ;
Feldman, Darren R. ;
Olencki, Thomas ;
Picus, Joel ;
Small, Eric J. ;
Dakhil, Shaker ;
George, Daniel J. ;
Morris, Michael J. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+
[4]   Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma [J].
Huang, Dan ;
Ding, Yan ;
Li, Yan ;
Luo, Wang-Mei ;
Zhang, Zhong-Fa ;
Snider, John ;
VandenBeldt, Kristin ;
Qian, Chao-Nan ;
Teh, Bin Tean .
CANCER RESEARCH, 2010, 70 (03) :1053-1062
[5]   Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma [J].
Hutson, Thomas E. ;
Escudier, Bernard ;
Esteban, Emilio ;
Bjarnason, Georg A. ;
Lim, Ho Yeong ;
Pittman, Kenneth B. ;
Senico, Peggy ;
Niethammer, Andreas ;
Lu, Dongrui Ray ;
Hariharan, Subramanian ;
Motzer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) :760-+
[6]   Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial [J].
Hutson, Thomas E. ;
Lesovoy, Vladimir ;
Al-Shukri, Salman ;
Stus, Viktor P. ;
Lipatov, Oleg N. ;
Bair, Angel H. ;
Rosbrook, Brad ;
Chen, Connie ;
Kim, Sinil ;
Vogelzang, Nicholas J. .
LANCET ONCOLOGY, 2013, 14 (13) :1287-1294
[7]   First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC [J].
Ko, J. J. ;
Choueiri, T. K. ;
Rini, B. I. ;
Lee, J-L ;
Kroeger, N. ;
Srinivas, S. ;
Harshman, L. C. ;
Knox, J. J. ;
Bjarnason, G. A. ;
MacKenzie, M. J. ;
Wood, L. ;
Vaishampayan, U. N. ;
Agarwal, N. ;
Pal, S. K. ;
Tan, M-H ;
Rha, S. Y. ;
Yuasa, T. ;
Donskov, F. ;
Bamias, A. ;
Heng, D. Y. C. .
BRITISH JOURNAL OF CANCER, 2014, 110 (08) :1917-1922
[8]   RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial [J].
Lee, J. L. ;
Kim, M. K. ;
Park, I. ;
Ahn, J. -H. ;
Lee, D. H. ;
Ryoo, H. M. ;
Song, C. ;
Hong, B. ;
Hong, J. H. ;
Ahn, H. .
ANNALS OF ONCOLOGY, 2015, 26 (11) :2300-2305
[9]   False positive rates of randomized Phase II designs [J].
Liu, PY ;
LeBlanc, M ;
Desai, M .
CONTROLLED CLINICAL TRIALS, 1999, 20 (04) :343-352
[10]   Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].
Motzer, Robert J. ;
Hutson, Thomas E. ;
Tomczak, Piotr ;
Michaelson, M. Dror ;
Bukowski, Ronald M. ;
Rixe, Olivier ;
Oudard, Stephane ;
Negrier, Sylvie ;
Szczylik, Cezary ;
Kim, Sindy T. ;
Chen, Isan ;
Bycott, Paul W. ;
Baum, Charles M. ;
Figlin, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124
12